S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

Microbot Medical Stock Price, Forecast & Analysis (NASDAQ:MBOT)

$5.01
+0.15 (+3.09 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$4.87
Now: $5.01
$5.29
50-Day Range
$4.64
MA: $5.30
$6.49
52-Week Range
$1.38
Now: $5.01
$19.40
Volume78,700 shs
Average Volume606,450 shs
Market Capitalization$21.58 million
P/E RatioN/A
Dividend YieldN/A
Beta5
Microbot Medical Inc, a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBOT
CUSIPN/A
Phone781-875-3605

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.40 per share

Profitability

Net Income$-7,240,000.00

Miscellaneous

Employees9
Market Cap$21.58 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive MBOT News and Ratings via Email

Sign-up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.


Microbot Medical (NASDAQ:MBOT) Frequently Asked Questions

What is Microbot Medical's stock symbol?

Microbot Medical trades on the NASDAQ under the ticker symbol "MBOT."

When did Microbot Medical's stock split? How did Microbot Medical's stock split work?

Microbot Medical shares reverse split on Monday, May 9th 2016. The 1-12 reverse split was announced on Friday, May 6th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 6th 2016. An investor that had 100 shares of Microbot Medical stock prior to the reverse split would have 8 shares after the split.

How were Microbot Medical's earnings last quarter?

Microbot Medical Inc (NASDAQ:MBOT) announced its quarterly earnings data on Wednesday, November, 14th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping analysts' consensus estimates of ($0.60) by $0.02. View Microbot Medical's Earnings History.

When is Microbot Medical's next earnings date?

Microbot Medical is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Microbot Medical.

What price target have analysts set for MBOT?

2 equities research analysts have issued 12 month price targets for Microbot Medical's shares. Their forecasts range from $1.75 to $10.00. On average, they expect Microbot Medical's stock price to reach $5.88 in the next year. This suggests a possible upside of 17.3% from the stock's current price. View Analyst Price Targets for Microbot Medical.

What is the consensus analysts' recommendation for Microbot Medical?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Microbot Medical in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Microbot Medical.

What are Wall Street analysts saying about Microbot Medical stock?

Here are some recent quotes from research analysts about Microbot Medical stock:
  • 1. According to Zacks Investment Research, "Microbot Medical Inc. is engaged in the research, design, development and commercialization of micro-robotics assisted medical technologies. Its product candidate includes the Self Cleaning Shunt for the treatment of hydrocephalus and Normal Pressure Hydrocephalus and TipCAT, a self-propelling, semi-disposable endoscope which is being developed initially for use in colonoscopy procedures. Microbot Medical Inc., formerly known as Stemcells, Inc., is headquartered in Hingham, MA. " (11/7/2019)
  • 2. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $60M, which includes a discounted cash flow (DCF)-based asset value of SCS, assuming 60% probability of approval, 20% discount rate and 2% terminal growth rate." (9/11/2019)

Has Microbot Medical been receiving favorable news coverage?

News headlines about MBOT stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Microbot Medical earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Microbot Medical.

Are investors shorting Microbot Medical?

Microbot Medical saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 73,500 shares, a decrease of 7.0% from the September 30th total of 79,000 shares. Based on an average daily trading volume, of 89,800 shares, the short-interest ratio is currently 0.8 days. Approximately 2.9% of the shares of the company are sold short. View Microbot Medical's Current Options Chain.

Who are some of Microbot Medical's key competitors?

What other stocks do shareholders of Microbot Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Microbot Medical investors own include TransEnterix (TRXC), Advanced Micro Devices (AMD), Athersys (ATHX), Alibaba Group (BABA), General Electric (GE), Novavax (NVAX), NVIDIA (NVDA), NovaBay Pharmaceuticals (NBY), Micron Technology (MU) and Gilead Sciences (GILD).

Who are Microbot Medical's key executives?

Microbot Medical's management team includes the folowing people:
  • Mr. Harel Gadot, Co-Founder, Pres, CEO & Chairman (Age 46)
  • Mr. David Ben Naim CPA, M.B.A., Chief Financial Officer (Age 50)
  • Dr. Simon Sharon, CTO & Chairman of Scientific Advisory Board
  • Prof. Moshe Shoham, Co-Founder, Scientific Director & Member of Scientific Advisory Board (Age 67)
  • Dr. Eric C. Leuthardt, Scientific Director & Member of Scientific Advisory Board

How do I buy shares of Microbot Medical?

Shares of MBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Microbot Medical's stock price today?

One share of MBOT stock can currently be purchased for approximately $5.01.

How big of a company is Microbot Medical?

Microbot Medical has a market capitalization of $21.58 million. The biotechnology company earns $-7,240,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Microbot Medical employs 9 workers across the globe.View Additional Information About Microbot Medical.

What is Microbot Medical's official website?

The official website for Microbot Medical is http://www.microbotmedical.com/.

How can I contact Microbot Medical?

Microbot Medical's mailing address is 25 RECREATION PARK DRIVE UNIT 108, HINGHAM MA, 02043. The biotechnology company can be reached via phone at 781-875-3605 or via email at [email protected]


MarketBeat Community Rating for Microbot Medical (NASDAQ MBOT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  520
MarketBeat's community ratings are surveys of what our community members think about Microbot Medical and other stocks. Vote "Outperform" if you believe MBOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel